We are expanding
our team.

Our mission is to develop therapies that cure and significantly improve survival for cancer patients.

 

Stemcentrx has assembled a talented and motivated team committed to this mission. We are recruiting people with world-class expertise in their practice, versatility, high energy and an entrepreneurial spirit.

Our state-of-the-art laboratories and manufacturing facilities are located in South San Francisco, California. We have a driven, ambitious, focused, hard-working, apolitical, fun, and collaborative culture.

 

In June 2016, Stemcentrx was acquired by AbbVie, a global, research-based biopharmaceutical company.

 

AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.